MUMBAI: The stellar performance of Mankind Pharma Ltd since its listing in Mumbai in May could trigger more consumer-related initial public offerings in India in the second half, according to bankers.
The company, which raised 43.3 billion rupee ($528 million) in India’s second-largest new share sale this year, has seen its shares jump 57% in almost two months, drawing a rush of buy calls from analysts.
